Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Chang, Li Sheng ^a,b   Leng, Chih Hsiang ^b   Yeh, Yi Chen ^b   Wu, Chiao Chieh ^b   Chen, Hsin Wei ^b,c   Huang, Hai Mei ^a   Liu, Shih Jen ^b,c  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Human papillomavirus; Immunotherapy; Innate receptor; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; RECOMBINANT LIPOPROTEIN; TOLL LIKE RECEPTOR 9 AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MUTANT; NONHUMAN; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UTERINE CERVIX CANCER;

ANIMALS; CANCER VACCINES; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; LIPOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGODEOXYRIBONUCLEOTIDES; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 9; TUMOR MICROENVIRONMENT; UTERINE CERVICAL NEOPLASMS;

EID: 84899535581     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-60     Document Type: Article

References (41)

1. Berzofsky JA, Terabe M, Wood LV. Strategies to use immune modulators in therapeutic vaccines against cancer. Semin Oncol 2012, 39:348-357. 10.1053/j.seminoncol.2012.02.002, 3356566, 22595057.
2. Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res 2013, 73:2381-2388. 10.1158/0008-5472.CAN-12-3932, 23580578.
3. Chouaib S. Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy. J Clin Invest 2003, 111:595-597. 10.1172/JCI18044, 151911, 12618511.
4. Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, Celis E, Pisarev V, Sherman S, Sporn MB, Gabrilovich D. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest 2011, 121:4015-4029. 10.1172/JCI45862, 3195459, 21911941.
5. James E, Yeh A, King C, Korangy F, Bailey I, Boulanger DS, Van den Eynde BJ, Murray N, Elliott TJ. Differential suppression of tumor-specific CD8+ T cells by regulatory T cells. J Immunol 2010, 185:5048-5055. 10.4049/jimmunol.1000134, 20921533.
6. Pittet MJ. Behavior of immune players in the tumor microenvironment. Curr Opin Opthalmol 2009, 21:53-59.
7. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol 2012, 33:119-126. 10.1016/j.it.2011.12.001, 3294003, 22277903.
8. Young MR, Wright MA, Pandit R. Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas. J Immunol 1997, 159:990-996.
9. Subiza JL, Vinuela JE, Rodriguez R, Gil J, Figueredo MA, De La Concha EG. Development of splenic natural suppressor (NS) cells in Ehrlich tumor-bearing mice. Int J Cancer 1989, 44:307-314. 10.1002/ijc.2910440220, 2527208.
10. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003, 9:606-612.
11. Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL. Characteristics of CD4 + CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005, 92:913-920. 10.1038/sj.bjc.6602407, 2361917, 15714205.
12. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169:2756-2761.
13. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Danie B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949. 10.1038/nm1093, 15322536.
14. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005, 115:3623-3633. 10.1172/JCI25947, 1288834, 16308572.
15. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007, 110:3192-3201. 10.1182/blood-2007-06-094615, 2200901, 17616639.
16. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, Takeda K, Akira S. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001, 13:933-940. 10.1093/intimm/13.7.933, 11431423.
17. Hertz CJ, Kiertscher SM, Godowski PJ, Bouis DA, Norgard MV, Roth MD, Modlin RL. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J Immunol 2001, 166:2444-2450.
18. Leng CH, Chen HW, Chang LS, Liu HH, Liu HY, Sher YP, Chang YW, Lien SP, Huang TY, Chen MY, Chou AH, Chong P, Liu SJ. A recombinant lipoprotein containing an unsaturated fatty acid activates NF-kappaB through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide. Mole Immunol 2010, 47:2015-2021.
19. Huang CY, Chen JJ, Shen KY, Chang LS, Yeh YC, Chen IH, Chong P, Liu SJ, Leng CH. Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model. PLoS One 2012, 7:e40970. 10.1371/journal.pone.0040970, 3399806, 22815882.
20. Liu C, Lou Y, Lizee G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, Wang G, Hwu P. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 2008, 118:1165-1175. 2230660, 18259609.
21. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010, 11:889-896. 10.1038/ni.1937, 20856220.
22. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005, 6:769-776. 10.1038/ni1223, 3760217, 15995707.
23. Krumbiegel D, Zepp F, Meyer CU. Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells. Hum Immunol 2007, 68:813-822. 10.1016/j.humimm.2007.08.001, 17961769.
24. Grossmann C, Tenbusch M, Nchinda G, Temchura V, Nabi G, Stone GW, Kornbluth RS, Uberla K. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands. BMC Immunol 2009, 10:43. 10.1186/1471-2172-10-43, 2731061, 19650904.
25. Zhu Q, Egelston C, Vivekanandhan A, Uematsu S, Akira S, Klinman DM, Belyakov IM, Berzofsky JA. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc Natl Acad Sci U S A 2008, 105:16260-16265. 10.1073/pnas.0805325105, 2570973, 18845682.
26. Shirota Y, Shirota H, Klinman DM. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol 2012, 188:1592-1599. 10.4049/jimmunol.1101304, 3273593, 22231700.
27. Huang Z, Yang Y, Jiang Y, Shao J, Sun X, Chen J, Dong L, Zhang J. Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers. Biomaterials 2013, 34:746-755. 10.1016/j.biomaterials.2012.09.062, 23107297.
28. Peng J, Tsang JY, Li D, Niu N, Ho DH, Lau KF, Lui VC, Lamb JR, Chen Y, Tam PK. Inhibition of TGF-beta signaling in combination with TLR7 ligation re-programs a tumoricidal phenotype in tumor-associated macrophages. Cancer Lett 2013, 331:239-249. 10.1016/j.canlet.2013.01.001, 23318200.
29. Zhang Y, Luo F, Cai Y, Liu N, Wang L, Xu D, Chu Y. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J Immunol 2011, 186:1963-1969. 10.4049/jimmunol.1002320, 21217015.
30. Jacobs C, Duewell P, Heckelsmiller K, Wei J, Bauernfeind F, Ellermeier J, Kisser U, Bauer CA, Dauer M, Eigler A, Maraskovsky E, Endres S, Schnurr M. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer 2011, 128:897-907. 10.1002/ijc.25399, 20473889.
31. Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, Schmid B, Schmitt E, Schild H, Radsak MP. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 2006, 108:544-550. 10.1182/blood-2005-10-4015, 16537810.
32. Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, Klinman DM, Berzofsky JA. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 2010, 120:607-616. 10.1172/JCI39293, 2811160, 20101095.
33. Zoglmeier C, Bauer H, Norenberg D, Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S, Bourquin C. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res 2011, 17:1765-1775. 10.1158/1078-0432.CCR-10-2672, 21233400.
34. LaRosa DF, Gelman AE, Rahman AH, Zhang J, Turka LA, Walsh PT. CpG DNA inhibits CD4 + CD25+ Treg suppression through direct MyD88-dependent costimulation of effector CD4+ T cells. Immunol Lett 2007, 108:183-188. 10.1016/j.imlet.2006.12.007, 1862558, 17270282.
35. Lepique AP, Daghastanli KR, Cuccovia IM, Villa LL. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res 2009, 15:4391-4400. 10.1158/1078-0432.CCR-09-0489, 19549768.
36. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555. 10.1016/S1471-4906(02)02302-5, 12401408.
37. Badylak SF, Valentin JE, Ravindra AK, McCabe GP, Stewart-Akers AM. Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue Eng Part A 2008, 14:1835-1842. 10.1089/ten.tea.2007.0264, 18950271.
38. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005, 65:3437-3446.
39. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996, 56:21-26.
40. Brasel K, De Smedt T, Smith JL, Maliszewski CR. Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood 2000, 96:3029-3039.
41. Sher YP, Liu SJ, Chang CM, Lien SP, Chen CH, Han Z, Li LY, Chen JS, Wu CW, Hung MC. Cancer-targeted BikDD gene therapy elicits protective antitumor immunity against lung cancer. Mol Cancer Ther 2011, 10:637-647. 10.1158/1535-7163.MCT-10-0827, 21282355.